Skip to main content

CCTG Connection



Published:
Category: News
ESMO updates clinical practice guidelines based on CO21 results
The European Society for Medical Oncology has updated its clinical practice guidelines to formally recommend integrating structured exercise into the standard of care for patients following their colon cancer treatment. This change is the direct result of the 17 year CCTG CO21 CHALLENGE trial that showed that guided exercise can improve survival rates and reduce cancer recurrence. Read More

Published:
Category: Publications
Publication: CRC2 sub study
Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy, Detection of molecular residual disease using circulating tumor DNA (ctDNA) may enable postoperative risk stratification and guide adjuvant therapy. Read More

Published:
Category: Publications
Publication: General review OPTIMISE-ROR
International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: Read More

Published:
Category: Publications
Publication: General review HIV Eligibility in Canadian Cancer Clinical Trials
People living with HIV have historically been excluded from many cancer clinical trials, limiting their access to new therapies and reducing the generalizability of research. Recent recommendations from professional societies encourage broader inclusion. Read More

Published:
Category: Trials
Trial closure:  IND243
The IND243: A Phase II Study of RP-6306 in Patients with Advanced Cancer trial has permanently closed. This study sought to answer if the new drug, RP-6306, safe to use, and what effects does it have on cancer when given with standard treatment and if there are specific biomarkers, do patients have an improved response to treatment compared to those without the biomarker. Read More

Published:
Category: Trials
Trial closure:  two IND241 sub studies
There have been permanent closures of two IND241 sub studies: IND241 B: A Phase II Study of RP-6306 in Patients with CDK4/6-Inhibitor Treated ER+HER2- Metastatic Breast Cancer Receiving Gemcitabine IND241 D: A Phase II Study of Lunresertib Plus Camonsertib in Patients With CDK4/6 Inhibitor Treated ER+/HER2- Metastatic Breast Cancer Read More



Published:
Category: Group updates
CCTG Recognition Awards Nominations 2026
The Canadian Cancer Trials Group is seeking nominations for the 2026 Recognition Awards honouring individuals who have contributed significantly to the mission and activities of the Group. Read More

Published:
Category: Group updates
2026 Annual Spring Meeting of Participants

The CCTG Annual Spring Meeting of Participants will be held Friday, April 24 to Sunday, April 26 at the Chelsea Hotel in Toronto.  Additionally, there are Workshops being held on Thursday, April 23, which are closed and by invitation only. These workshops will require a separate invitation and registration, and attendees invited to a Workshop in addition to the Spring Meeting must register for both. 

Read More